Targeting RAS–ERK signalling in cancer: promises and challenges
The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes. Recently, the use of compounds targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clinical outcome in metastatic melanoma and has shown promising clinical activity in additional tumour types. However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance. Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently associated with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The activity of single agent therapies targeting individual RAS effector pathways is limited”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“combinations of inhibitors targeting multiple effector and/or feedback pathways have shown impressive activity in KRAS mutant model systems”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“Determinants of primary resistance are not the same in different tumor types that up-regulate various RTKs or their ligands in response to pathway inhibition (111-113).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [113]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Cited by
Items 401–500 of 1,000
Weissman, R., Diamond, E. L., Haroche, J., Durham, B. H., Aubart, F. C., Buthorn, J. J., Amoura, Z., Emile, J., Mazor, R. D., Shomron, N., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01472-2 · Cited by 26
Multifunctionality of Calebin A in inflammation, chronic diseases and cancer
Brockmueller, A., Mueller, A., Kunnumakkara, A. B., Aggarwal, B. B., & Shakibaei, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.962066 · Cited by 29
Wallon, L., Khan, I., Teng, K. W., Koide, A., Zuberi, M., Li, J., Ketavarapu, G., Traaseth, N. J., O’Bryan, J. P., & Koide, S. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204481119 · Cited by 26
Ribosomal S6 kinase (RSK) modulators: a patent review
Ludwik, K. A., & Lannigan, D. A. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1212839 · Cited by 28
Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis
Xie, J., Shen, K., Jones, A. T., Yang, J., Tee, A. R., Shen, M. H., Yu, M., Irani, S., Wong, D., Merrett, J. E., et al. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03491-1 · Cited by 30
P2Y2 receptor activation promotes esophageal cancer cells proliferation via ERK1/2 pathway
Zaparte, A., Cappellari, A. R., Brandão, C. A., de Souza, J. B., Borges, T. J., Kist, L. W., Bogo, M. R., Zerbini, L. F., Pinto, L. F. R., Glaser, T., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173687 · Cited by 29
Huestis, M. P., Cruz, D. D., DiPasquale, A. G., Durk, M. R., Eigenbrot, C. W., Gibbons, P., Gobbi, A., Hunsaker, T., La, H., Leung, D. H., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02085 · Cited by 26
Approaches for targeting cancer stem cells drug resistance
Rosa, R., D’Amato, V., Placido, S. D., & Bianco, R. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1243525 · Cited by 28
Bognár, Z., Fekete, K., Antus, C., Hocsák, E., Bognar, R., Tapodi, A., Boronkai, Á., Farkas, N., Gallyas, F., Sümegi, B., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189470 · Cited by 25
Fan, Y., Arechederra, M., Richelme, S., Daian, F., Novello, C., Caldéraro, J., Tommaso, L. D., Morcrette, G., Rebouissou, S., Donadon, M., et al. (2017) · Hepatology · doi:10.1002/hep.29304 · Cited by 32
Lin, Y.-H. T., Way, G. P., Barwick, B. G., Mariano, M. C., Marcoulis, M., Ferguson, I., Driessen, C., Boise, L., Greene, C. S., & Wiita, A. P. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000303 · Cited by 26
Li, Y., Dong, Q., & Cui, Y. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0137 · Cited by 29
LY6K promotes glioblastoma tumorigenicity via CAV-1–mediated ERK1/2 signaling enhancement
Sastry, N. G., Wan, X., Huang, T., Alvarez, A. A., Pangeni, R. P., Song, X., James, C. D., Horbinski, C., Brennan, C., Nakano, I., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa032 · Cited by 26
Grbovic-Huezo, O., Pitter, K. L., Lecomte, N., Saglimbeni, J. A., Aşkan, G., Holm, M., Melchor, J. P., Chandwani, R., Joshi, S., Haglund, C. H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920240117 · Cited by 24
Huang, S., Chen, Y., Jia, Y., Yang, T., Su, W., Zhu, Z., Xue, P., Feng, F., Zhao, Y., & Chen, G. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108835 · Cited by 27
Luo, Q., & Yin, J. (2021) · Bioengineered · doi:10.1080/21655979.2021.1987067 · Cited by 25
Recent advances in B-RAF inhibitors as anticancer agents
Khan, P. S., Rajesh, P., Rajendra, P., Chaskar, M. G., Arote, R. B., & Sangshetti, J. N. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105597 · Cited by 27
Pediatric Acute Lymphoblastic Leukemia Emerging Therapies—From Pathway to Target
Ivanov, A. V., Alecsa, M., Popescu, R. M., Stârcea, I. M., Mocanu, A., Rusu, C., & Miron, I. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054661 · Cited by 32
Bidirectional interplay between SARS-CoV-2 and autophagy
Zhou, H., Hu, Z., & Castro‐Gonzalez, S. (2023) · mBio · doi:10.1128/mbio.01020-23 · Cited by 30
Optimization Of Cancer Treatment Through Overcoming Drug Resistance
Elshimali, Y., Wu, Y., Khaddour, H., Wu, Y., Grădinaru, D., Sukhija, H., CHUNG, S. S., & Vadgama, J. V. (2018) · Journal of Cancer Research and Oncobiology · doi:10.31021/jcro.20181107 · Cited by 25
First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia
Cho, H., Shin, I., Ju, E., Choi, S.-H., Hur, W., Kim, H., Hong, E., Kim, N. D., Choi, H. G., Gray, N. S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00882 · Cited by 25
zu Belzen, J. U., Buergel, T., Holderbach, S., Bubeck, F., Adam, L., Gandor, C. L. A., Klein, M., Mathony, J., Pfuderer, P. L., Platz, L., et al. (2019) · Nature Machine Intelligence · doi:10.1038/s42256-019-0049-9 · Cited by 29
Wang, W., Park, C., Oh, E., Sung, Y., Lee, J., Park, K.-H., & Kang, H. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00646 · Cited by 25
Schönholzer, M. T., Migliavacca, J., Alvarez, E., Kumar, K. S., Neve, A., Gries, A., Ma, M., Grotzer, M. A., & Baumgartner, M. (2020) · Neoplasia · doi:10.1016/j.neo.2020.07.006 · Cited by 22
Lim, C., Kang, X., Mirabella, V. R., Zhang, H., Bu, Q., Araki, Y., Hoang, E. T., Wang, S., Shen, Y., Choi, S., et al. (2017) · Genes & Development · doi:10.1101/gad.294413.116 · Cited by 26
GCN5–ERK lactylation–phosphorylation loop amplifies lactate-driven cancer progression
Huang, B., Jin, M., Cui, G., Wang, Z., Wang, F., Chen, M., Zhu, L., Li, Y., Yang, X., Li, R., et al. (2026) · Nature Chemical Biology · doi:10.1038/s41589-025-02107-8 · Cited by 24
Ji, W., Chen, J., Mi, Y., Wang, G., XU, X., & Wang, W. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3519 · Cited by 24
CLIC1 promotes the progression of oral squamous cell carcinoma via integrins/ERK pathways.
Feng, J., Xu, J., Xu, Y. X., Xiong, J., Xiao, T., Jiang, C., Li, X., Wang, Q., Li, J., & Li, Y. (2019) · Europe PMC (PubMed Central) · Cited by 24
SREBP1 regulates mitochondrial metabolism in oncogenic KRAS expressing NSCLC
Ruiz, C. F., Montal, E. D., Haley, J. D., Bott, A. J., & Haley, J. D. (2020) · The FASEB Journal · doi:10.1096/fj.202000052r · Cited by 31
Minocycline in Treating Glioblastoma Multiforme: Far beyond a Conventional Antibiotic
Afshari, A. R., Mollazadeh, H., & Sahebkar, A. (2020) · Journal of Oncology · doi:10.1155/2020/8659802 · Cited by 27
Sun, C., Cao, D., Ren, Q., Zhang, S., Zhou, N., Mai, S., Feng, B. C., & Wang, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.684243 · Cited by 26
Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ERα-Positive Breast Cancer
Vafeiadou, V., Hany, D., & Picard, D. (2022) · Cancers · doi:10.3390/cancers14040954 · Cited by 27
Messeha, S. S., Zarmouh, N. O., Antonie, L. M., & Soliman, K. F. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158329 · Cited by 28
Xia, K., Zheng, D., Wei, Z., Liu, W., & Guo, W. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06048-9 · Cited by 29
Kedage, V., Strittmatter, B. G., Dausinas, P., & Hollenhorst, P. C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.796458 · Cited by 27
A Rationale for Targeting Extracellular Regulated Kinases ERK1 and ERK2 in Glioblastoma
Hannen, R., Hauswald, M., & Bartsch, J. W. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx076 · Cited by 28
Natural gypenosides: targeting cancer through different molecular pathways
Ahmad, B., Khan, S., Nabi, G., Gamallat, Y., Su, P., Jamalat, Y., Duan, P., & Yao, L. (2019) · Cancer Management and Research · doi:10.2147/cmar.s185232 · Cited by 26
Local Inhibition of MEK/Akt Prevents Cellular Growth in Human Congenital Melanocytic Nevi
Rouillé, T., Aractingi, S., Kadlub, N., Fraitag, S., How‐Kit, A., Daunay, A., Hivelin, M., Moguelet, P., Picard, A., Fontaine, R. H., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.03.1156 · Cited by 25
Anthrax: Transmission, Pathogenesis, Prevention and Treatment
Sangwan, N., Gangwal, A., Jain, P., Langtso, C., Srivastava, S., Dhawan, U., Baweja, R., & Singh, Y. P. (2025) · Toxins · doi:10.3390/toxins17020056 · Cited by 34
Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons
Ibrahim, S., Khan, M. U., Khurram, I., Rehman, R., Rauf, A., Ahmad, Z., Aljohani, A. S. M., Abdulmonem, W. A., & Quradha, M. M. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70011 · Cited by 30
Andreatos, N., Ronnekleiv‐Kelly, S. M., Margonis, G. A., Sasaki, K., Gani, F., Amini, N., Wilson, A., & Pawlik, T. M. (2016) · Surgical Oncology · doi:10.1016/j.suronc.2016.07.002 · Cited by 26
Dyshlovoy, S. A., Kaune, M., Hauschild, J., Kriegs, M., Hoffer, K., Busenbender, T., Smirnova, P. A., Zhidkov, M. E., Poverennaya, E. V., Oh‐Hohenhorst, S. J., et al. (2020) · Marine Drugs · doi:10.3390/md18120609 · Cited by 24
RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
Koh, S., Ross, K. N., Isakoff, S. J., Melkonjan, N., He, L., Matissek, K. J., Schultz, A., Mayer, E. L., Traina, T. A., Carey, L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0714 · Cited by 24
Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer
Zhang, Y., Liang, S., Saliakoura, M., Yang, H., Vassella, E., Konstantinidou, G., Tschan, M. P., Hegedűs, B., Zhao, L., Gao, Y., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013193 · Cited by 25
Garcia, N., Pozo, V. D., Yohe, M. E., Goodwin, C. M., Shackleford, T. J., Wang, L., Baxi, K., Chen, Y., Rogojina, A. T., Zimmerman, S. M., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0194 · Cited by 28
Hoffman, T. E., Nangia, V., Ill, C. R., Passanisi, V. J., Armstrong, C., Yang, C., & Spencer, S. L. (2023) · Science Signaling · doi:10.1126/scisignal.ade8744 · Cited by 22
Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma
Krepler, C., Xiao, M., Samanta, M., Vultur, A., Chen, H., Brafford, P. A., Reyes-Uribe, P. I., Halloran, M. B., Chen, T., He, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12078 · Cited by 23
Self-citationObesity and diabetes as prognostic factors in patients with colorectal cancer
Voutsadakis, I. A. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.12.018 · Cited by 23
Ding, J., Zhang, L., Zeng, S., & Feng, T. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.05.082 · Cited by 23
Addressing cancer signal transduction pathways with antisense and siRNA oligonucleotides
Juliano, R. L. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa025 · Cited by 30
Heightman, T. D., Berdini, V., Bevan, L., Buck, I. M., Carr, M. G., Courtin, A., Coyle, J. E., Day, J. E. H., East, C., Fazal, L., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00905 · Cited by 23
Xu, G., Luo, Y., Wu, W., Liu, X., Yu, X., Bao, Y., He, X., Yu, J., Li, Y., Yang, J., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.07.162 · Cited by 26
Liu, S., Ma, Q., Fattah, R. J., Bugge, T. H., & Leppla, S. H. (2017) · Oncotarget · doi:10.18632/oncotarget.17729 · Cited by 22
Sun, Y., Peng, W., He, W., Luo, M., Chang, G., Shen, J., Zhao, X., & Hu, Y. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0818-z · Cited by 25
Hu, C., Iwasaki, M., Liu, Z., Wang, B., Li, X., Lin, H., Li, J., Li, J. V., Lian, Q., & Ma, D. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2020.12.007 · Cited by 22
Lee, C.-I., Liao, C., Chen, C.-S., Cheng, F., Chung, Y.-H., Wang, Y.-C., Ciou, S.-Y., Hsueh, W.-Y., Lo, T.-H., Huang, G.-R., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104715 · Cited by 23
Payne, K. F. B., Brooks, J. M., Batis, N., Khan, N., El‐Asrag, M. E., Nankivell, P., Mehanna, H. M., & Taylor, G. S. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02428-2 · Cited by 21
Two decades of a protooncogene TBL1XR1: from a transcription modulator to cancer therapeutic target
Du, R., Li, K., Guo, K., Chen, Z., Zhao, X., Han, L., & Bian, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1309687 · Cited by 22
Djuzenova, C. S., Fiedler, V., Katzer, A., Michel, K., Deckert, S., Zimmermann, H., Sukhorukov, V. L., & Flentje, M. P. (2016) · Oncotarget · doi:10.18632/oncotarget.9501 · Cited by 23
PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK
Lu, T., Zou, Y., Xu, G., Potter, J. A., Taylor, G. L., Duan, Q., Yang, Q., Xiong, H., Qiu, H., Ye, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12940 · Cited by 22
KAP1 inhibits the Raf‐MEK‐ERK pathway to promote tumorigenesis in A549 lung cancer cells
Wu, G., Pen, J., Huang, Y., An, S., Liu, Y., Yang, Y., Hao, Q., Guo, X., & Xu, T. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22853 · Cited by 22
Localization dynamics of endogenous fluorescently labeled RAF1 in EGF-stimulated cells
Surve, S., Myers, P. J., Clayton, S. A., Watkins, S. C., Lazzara, M. J., & Sorkin, A. D. (2018) · Molecular Biology of the Cell · doi:10.1091/mbc.e18-08-0512 · Cited by 24
Bostan, M., Petrică-Matei, G. G., Ion, G., Radu, N., Mihaila, M. A., Hainăroșie, R., Braşoveanu, L. I., Roman, V., Constantin, C., & Neagu, M. T. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8139 · Cited by 22
Zhang, X., Shen, R., Shu, Z., Zhang, Q., & Chen, Z. (2020) · Pathology International · doi:10.1111/pin.12924 · Cited by 22
Guerrero, P., Albarrán, V., San Román, M., González-Merino, C., García de Quevedo, C., Moreno, J., Calvo, J. C., González, G., Orejana, I., Chamorro, J., et al. (2023) · Cancers · doi:10.3390/cancers15215243 · Cited by 21
Regulated programmed cell death in sepsis associated acute lung injury: From pathogenesis to therapy
Deng, R., Huang, G., Wang, T., & Zhou, J. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114111 · Cited by 22
β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
Ganesh, S., Shui, X., Craig, K. P., Koser, M. L., Chopda, G. R., Cyr, W. A., Lai, C.-J., Dudek, H., Wang, W., Brown, B. D., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0605 · Cited by 21
At the Crossroads: Mechanisms of Apoptosis and Autophagy in Cell Life and Death
Shliapina, V. L., Yurtaeva, S. V., Rubtsova, M. P., & Dontsova, O. А. (2021) · Acta Naturae · doi:10.32607/actanaturae.11208 · Cited by 22
Song, F., Chen, F.-Y., Wu, S., Hu, B., Liang, X., Yang, H.-Q., Cheng, J., Wang, P., Guo, W. P., Zhou, J., et al. (2021) · Journal of Cancer · doi:10.7150/jca.63235 · Cited by 22
Puyalto, A., Rodríguez‐Remírez, M., López, I., Macaya, I., Guruceaga, E., Olmedo, M., Vilalta, A., Welch, C., Sandiego, S., Vicent, S., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01991-3 · Cited by 22
Challenges in the Delivery of Therapies to Melanoma Brain Metastases
Gampa, G., Vaidhyanathan, S., Wilken-Resman, B., Parrish, K. E., Markovic, S. N., Sarkaria, J. N., & Elmquist, W. F. (2016) · Current Pharmacology Reports · doi:10.1007/s40495-016-0072-z · Cited by 23
Zhang, S., Xu, Y., Jin, E., Zhu, L., Xia, B., Chen, X., Li, F., & Ma, S. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.116 · Cited by 23
Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond
Zhou, A. Y., & Johnson, D. B. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0320-y · Cited by 26
Zhang, J., Jiao, K., Liu, J., & Xia, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.9382 · Cited by 24
Bioorthogonal Engineering of Bacterial Effectors for Spatial–Temporal Modulation of Cell Signaling
Zhao, J., Liu, Y., Lin, F., Wang, W., Yang, S., Ge, Y., & Chen, P. R. (2018) · ACS Central Science · doi:10.1021/acscentsci.8b00751 · Cited by 22
Gampa, G., Kim, M., Mohammad, A. S., Parrish, K. E., Mladek, A. C., Sarkaria, J. N., & Elmquist, W. F. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.253708 · Cited by 22
MicroRNA‑665 promotes the proliferation of ovarian cancer cells by targeting SRCIN1
Zhou, P., Xiong, T., Yao, L., & Yuan, J. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8293 · Cited by 21
Cabrera‐Andrade, A., López‐Cortés, A., Jaramillo-Koupermann, G., Paz‐y‐Miño, C., Pérez‐Castillo, Y., Munteanu, C. R., González‐Díaz, H., Pazos, A., & Tejera, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031053 · Cited by 23
SOS1 interacts with Grb2 through regions that induce closed nSH3 conformations
Liao, T.-J., Jang, H., Fushman, D., & Nussinov, R. (2020) · The Journal of Chemical Physics · doi:10.1063/5.0013926 · Cited by 20
Selective CRAF Inhibition Elicits Transactivation
Morgan, C. W., Dale, I. L., Thomas, A. P., Hunt, J., & Chin, J. W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c11958 · Cited by 22
Pyakurel, A., Balmer, D., Saba-El-Leil, M. K., Kizilyaprak, C., Daraspe, J., Humbel, B. M., Voisin, L., Le, Y. Z., von Lintig, J., Meloche, S., et al. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00295-17 · Cited by 20
Tiwari, A., Rahi, S., & Mehan, S. (2020) · Current Drug Targets · doi:10.2174/1389450121666201020155010 · Cited by 19
Magnetic nanoparticles in theranostics of malignant melanoma
Shevtsov, M. A., Kaesler, S., Posch, C., Multhoff, G., & Biedermann, T. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00868-6 · Cited by 21
Hypoxia Induces Autophagy in Human Dendritic Cells: Involvement of Class III PI3K/Vps34
Monaci, S., Coppola, F., Rossi, D., Giuntini, G., Filippi, I., Marotta, G., Sozzani, S., Carraro, F., & Naldini, A. (2022) · Cells · doi:10.3390/cells11101695 · Cited by 20
ERK2 MAP kinase regulates SUFU binding by multisite phosphorylation of GLI1
Bardwell, A. J., Wu, B., Sarin, K. Y., Waterman, M. L., Atwood, S. X., & Bardwell, L. (2022) · Life Science Alliance · doi:10.26508/lsa.202101353 · Cited by 20
Yi, Q., Peng, J., Xu, Z., Liang, Q., Cai, Y., Peng, B., He, Q., & Yan, Y. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.806851 · Cited by 25
Shi, C.-J., Xue, Z.-H., Zeng, W.-Q., Deng, L.-Q., Pang, F., Zhang, F., Fu, W.-M., & Zhang, J. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00595-1 · Cited by 21
Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities
Radic-Sarikas, B., Tsafou, K. P., Emdal, K. B., Papamarkou, T., Huber, K., Mutz, C., Toretsky, J. A., Bennett, K. L., Olsen, J. V., Brunak, S., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0235 · Cited by 20
Tsubaki, M., Takeda, T., Kino, T., Sakai, K., Itoh, T., Imano, M., Nakayama, T., Nishio, K., Satou, T., & Nishida, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16314 · Cited by 21
Optogenetic Control of Ras/Erk Signaling Using the Phy–PIF System
Goglia, A. G., Wilson, M. Z., DiGiorno, D. B., & Toettcher, J. E. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7154-1_1 · Cited by 20
Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2 -Amplified Gastric Cancer
Sase, H., Nakanishi, Y., Aida, S., Horiguchi-Takei, K., Akiyama, N., Fujii, T., Sakata, K., Mio, T., Aoki, M., & Ishii, N. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1022 · Cited by 21
García-Torres, D., & Fierke, C. A. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007438 · Cited by 22
KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K–MAPK1 inhibition
Janardhan, H. P., Meng, X., Dresser, K., Hutchinson, L., & Trivedi, C. M. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20192205 · Cited by 22
Cunningham, D. L., Sarhan, A. R., Creese, A. J., Larkins, K. P. B., Zhao, H., Ferguson, H. R., Brookes, K., Marusiak, A. A., Cooper, H. J., & Heath, J. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-64534-y · Cited by 19
Dyshlovoy, S. A., Kaune, M., Kriegs, M., Hauschild, J., Busenbender, T., Shubina, L. K., Makarieva, T. N., Hoffer, K., Bokemeyer, C., Graefen, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69751-z · Cited by 20
Liu, Z., Fu, Q., Wang, Y., Cui, L., Zhang, W., Teng, Y., & Yu, P. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111144 · Cited by 22
Chen, P., Chen, G., Wang, C., & Mao, C. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.08.141 · Cited by 22
Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities
Zhang, J., Park, D., Shin, D. M., & Deng, X. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv118 · Cited by 23
Goh, Y.-Y., Yan, Y. K., Tan, N. S., Goh, S.-A., Li, S., Teoh, Y.-C., & Lee, P. P. F. (2016) · Scientific Reports · doi:10.1038/srep36868 · Cited by 19
Wang, X., Dai, C., Yin, Y., Wu, L., Jin, W., Fu, Y., Chen, Z., Hao, K., & Lü, B. (2021) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2000842 · Cited by 18
Metadata
- Authors
- Samatar, A. A., & Poulikakos, P. I.
- Affiliations
- Tisch Cancer Institute (US)
- Corresponding author
- Poulikakos, Poulikos I.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-12
- Volume
- 13
- Issue
- 12
- Pages
- 928-942
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2050573392
- Cited by
- 1,163
- References
- 139
- Citations by year
- 2026: 47 · 2025: 77 · 2024: 106 · 2023: 100 · 2022: 102 · 2021: 134 · 2020: 119 · 2019: 105 · 2018: 117 · 2017: 101 · 2016: 108 · 2015: 45 · 2014: 2
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- RAF inhibitors, MEK inhibitors, ERK inhibitor, KRAS mutation, NRAS mutation, BRAF mutation, acquired drug resistance, intrinsic drug resistance, metastatic melanoma, targeted cancer therapy, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Delivery Systems, ras Proteins, MAP Kinase Signaling System, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.